Publications by authors named "T Sliwa"
Article Synopsis
- Researchers used genetically engineered mice and cell lines to study how the depletion of endoplasmic reticulum (ER) calcium stores activates specific calcium entry channels (SOCE) that primarily rely on Orai1 molecules.
- They discovered that Orai1 is the dominant calcium entry pathway compared to Orai2 and Orai3, and this process does not require functional TRPC molecules, as shown by experiments using cells with inactive TRPC genes.
- The study also found that even though the TRPC genes were disrupted, both store-depletion-activated calcium entry and receptor-operated calcium entry (ROCE) still relied on Orai1, leading to the establishment of a new strain of mice called TRPC heptaKO mice, which are
Approximately 15% of newly diagnosed breast cancer patients have neither hormone receptors expression nor HER2 overexpression and/or HER2/neu gene amplification. This subtype of breast cancer is known as Triple Negative Breast Cancer (TNBC), and carries a significantly elevated risk of local and distant recurrence. In comparison with other breast cancer subtypes, there is a higher rate of visceral and brain metastases.
View Article and Find Full Text PDFMyeloproliferative neoplasms (MPN) are characterized by uncontrolled expansion of myeloid cells, disease-related mutations in certain driver-genes including JAK2, CALR, and MPL, and a substantial risk to progress to secondary acute myeloid leukemia (sAML). Although behaving as stem cell neoplasms, little is known about disease-initiating stem cells in MPN. We established the phenotype of putative CD34 /CD38 stem cells and CD34 /CD38 progenitor cells in MPN.
View Article and Find Full Text PDFArticle Synopsis
- * A study showed that CML patients had significantly more CD203c-positive leukocytes compared to healthy individuals, indicating a strong correlation between CD203c levels and disease risk.
- * Successful treatment with medications like imatinib led to a notable decrease in CD203c basophils, suggesting that CD203c could be used as a biomarker to monitor basophilia in CML patients throughout their treatment journey.
Article Synopsis
- A group of Austrian breast cancer specialists convened in December 2020 to evaluate the benefit-risk profiles of HER2-targeted therapies and create an updated treatment algorithm.
- Over several months in 2021, they developed four patient-specific treatment scenarios to assess optimal strategies.
- Detailed discussions were held to achieve full consensus on the treatment approaches for the different scenarios.